EU/3/10/768

About

On 25 August 2010, orphan designation (EU/3/10/768) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene for the treatment of primary myelofibrosis.

The sponsorship was transferred to Baxter Innovations GmbH, Austria, in March 2015.

The sponsorship was transferred to CTI Life Sciences Ltd, United Kingdom, in November 2016 and subsequently to CTI Life Sciences Deutschland GmbH, Germany, in May 2019.

This medicine is now known as pacritinib.

Key facts

Active substance
27000
Disease / condition
Treatment of primary myelofibrosis
Date of first decision
25/08/2010
Outcome
Positive
EU designation number
EU/3/10/768

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details


Universitaetsstrasse 71 
Lindenthal 
Cologne 
North Rhine-Westphalia 
50931 
Germany
Tel. +49 51187989019
E-mail: contactus@CTI-lifesciences.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating